Day One Biopharmaceuticals (NASDAQ:DAWN) PT Raised to $36.00

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective increased by JPMorgan Chase & Co. from $32.00 to $36.00 in a research note published on Monday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

DAWN has been the topic of a number of other reports. Piper Sandler restated an overweight rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Oppenheimer restated a market perform rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Finally, The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating for the company in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $39.83.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock opened at $15.38 on Monday. The company has a market capitalization of $1.34 billion, a P/E ratio of -6.46 and a beta of -1.48. The business has a 50-day moving average of $15.22 and a two-hundred day moving average of $13.75. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, equities analysts anticipate that Day One Biopharmaceuticals will post -2.66 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jeremy Bender sold 7,615 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $116,128.75. Following the completion of the sale, the chief executive officer now owns 721,813 shares of the company’s stock, valued at approximately $11,007,648.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jeremy Bender sold 7,615 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $116,128.75. Following the transaction, the chief executive officer now owns 721,813 shares in the company, valued at approximately $11,007,648.25. The disclosure for this sale can be found here. Insiders have sold 55,781 shares of company stock valued at $883,160 over the last ninety days. 8.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after purchasing an additional 1,262 shares during the period. Quest Partners LLC bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth approximately $29,000. Quintet Private Bank Europe S.A. raised its position in shares of Day One Biopharmaceuticals by 43.2% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after buying an additional 1,000 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after buying an additional 2,268 shares during the period. Finally, Exchange Traded Concepts LLC grew its position in Day One Biopharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after buying an additional 2,554 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.